Florida leukemia rates rising rapidly as population ages, study shows

Researchers discover gene that could help improve treatment decisions in childhood leukemia

A new type of cancer cell that “warrants urgent investigation” has been discovered in childhood leukaemia, and could impact clinical care. Research into new or repurposed treatments that target this new cell type could give hope to children and families worldwide.

November 14, 2025

Vol.51 No.42

Drugs & Targets

FDA approves Komzifti for r/r NPM1-mutated AML

FDA has granted full approval of Komzifti (ziftomenib) for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. Komzifti is the first and only once-daily, oral menin inhibitor approved for R/R NPM1-mutated AML, a devastating blood cancer with limited treatment options.

November 14, 2025

Vol.51 No.42

In Brief

Sylvester launches Survivorship and Supportive Care Institute

Sylvester Comprehensive Cancer Center, part of the University of Miami Health System and Miller School of Medicine, has announced the launch of the Sylvester Survivorship and Supportive Care Institute—a dedicated survivorship institute focused on meeting the full spectrum of needs of the growing cancer survivor population in South Florida.

November 07, 2025

Vol.51 No.41

Ci4CC’s 24th Symposium & Workshop set to focus on precision oncology powered by data intelligence

Chaired by the University of Miami Sylvester Comprehensive Cancer Center, the 24th Cancer Centers Informatics Society (Ci4CC) Symposium will convene the nation’s leading designated and community cancer centers with a central focus on advancing precision oncology.

Study assesses cancers in children exposed to medical imaging

Ten percent of pediatric blood and bone marrow cancers may have stemmed from radiation exposure, according to a study led by UC San Francisco and UC Davis.

September 26, 2025

Vol.51 No.35